How Rwanda mounted a research response with an investigational vaccine just ten days into a Marburg outbreak
Abstract The September 2024 outbreak of Marburg virus disease (MVD) represented the first time this virus was identified in Rwanda. Health authorities mounted a rapid and effective response, including the rapid execution of an open-label Phase 2 clinical trial of an investigational Marburg vaccine,...
Saved in:
| Main Authors: | Sabin Nsanzimana, Noella Bigirimana, Richard Hatchett, Sue Bailey, Natacha Butera, Yvan Butera, Jakob P. Cramer, Amy Finan, Caroline M. Forkin, Adam M. Hacker, Sibomana Hassan, Vicky Leamy, Vincent Mutabazi, Julien Nyombayire, Eric Remera, Edson Rwagasore, Eduardo Tedeschi, Kelly L. Warfield, Nicole Lurie |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-08-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-025-01224-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Refining early detection of Marburg Virus Disease (MVD) in Rwanda: Leveraging predictive symptom clusters to enhance case definitions
by: Olivier Nsekuye, et al.
Published: (2025-07-01) -
Evidence-Based Guidance for One Health Preparedness, Prevention, and Response Strategies to Marburg Virus Disease Outbreaks
by: Claude Mambo Muvunyi, et al.
Published: (2024-12-01) -
Marburg virus in Rwanda: challenges, strategies, and future directions
by: Majani Edward
Published: (2025-03-01) -
Marburg virus disease in Rwanda: an observational study of the first 10 days of outbreak response, clinical interventions, and outcomes
by: Gashaija Absolomon, et al.
Published: (2025-05-01) -
Marburg virus disease Mayhem: A new threat emerges in Rwanda
by: Pawan Kumar, et al.
Published: (2024-12-01)